ArticleCell stress & chaperones2026
Inhibition of α-1,3-mannosyltransferase sensitizes head and neck squamous cell carcinomas to cetuximab via endoplasmic reticulum stress.
Article in Cell stress & chaperones, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing effective therapeutic strategies for head and neck squamous cell carcinoma (HNSCC) remains a considerable clinical challenge. Cetuximab, a first-line targeted therapy for HNSCC, exhibits limited efficacy. The aim of this study was to explore the potential of α-1,3-mannosyltransferase (ALG3) inhibition in augmenting the therapeutic efficacy of cetuximab. We first analyzed the Cancer Genome Atlas (TCGA) data and found that ALG3 was significantly overexpressed in HNSCC tissues, correlating with worse pathological features and lower overall and disease-specific survival. Functional studies using ALG3-knockdown cells and a subcutaneous tumor model demonstrated that ALG3 inhibition markedly suppressed HNSCC proliferation both in vitro and in vivo. Furthermore, combining ALG3 inhibition with cetuximab elicited potent anti-cancer effects in vitro and in vivo. Mechanistic investigations via quantitative polymerase chain reaction, western blotting, and transmission electron microscopy revealed that ALG3 knockdown induced endoplasmic reticulum (ER) stress in HNSCC cells through the Bip/IRE1α axis. Finally, blocking N‑linked glycosylation synergistically enhanced cetuximab-mediated growth inhibition of HNSCC cells. In conclusion, ALG3 is a promising target to enhance the therapeutic efficacy of cetuximab in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.